Literature DB >> 27829277

Surgical management of biliary tract cancers.

Mark Fairweather1, Vinod P Balachandran2, Michael I D'Angelica3.   

Abstract

Biliary tract cancers (BTC) are aggressive gastrointestinal malignancies that are associated with a poor prognosis. This rare group of tumors includes cancers of the gallbladder, intrahepatic, and extrahepatic biliary tree. Chronic inflammatory processes such as cholelithiasis and chronic bacterial infection of the biliary system remain the most common underlying risk factor although most cases occur sporadically. The majority of patients present with advanced disease accompanied by nonspecific symptoms, making BTCs a therapeutic challenge for clinicians. In patients with localized, resectable disease, the only potentially curative treatment is a complete resection with negative microscopic margins. Liver transplantation has been used in selected patients with peri-hilar cholangiocarcinoma, with acceptable results. Recurrence rates remain high despite surgical treatment and 5-year survival rates range from 8-40% in patients treated with resection. In this review, we will summarize the current surgical management strategies for BTCs, focusing on the role of resection.

Entities:  

Keywords:  Biliary tract cancer (BTC); cholangiocarcinoma; gallbladder cancer

Mesh:

Year:  2016        PMID: 27829277     DOI: 10.21037/cco.2016.10.03

Source DB:  PubMed          Journal:  Chin Clin Oncol        ISSN: 2304-3865


  12 in total

1.  Dysplasia in Gallbladder: What Should We Do?

Authors:  Rehan Rais; Iván González; Deyali Chatterjee
Journal:  J Gastrointest Surg       Date:  2018-09-13       Impact factor: 3.452

2.  Surgical management of biliary malignancy.

Authors:  T Peter Kingham; Victoria G Aveson; Alice C Wei; Jason A Castellanos; Peter J Allen; Daniel P Nussbaum; Yinin Hu; Michael I D'Angelica
Journal:  Curr Probl Surg       Date:  2020-06-30       Impact factor: 1.909

3.  Suppression of miR-16 promotes tumor growth and metastasis through reversely regulating YAP1 in human cholangiocarcinoma.

Authors:  Sheng Han; Dong Wang; Guohua Tang; Xinxiang Yang; Chenyu Jiao; Renjie Yang; Yaodong Zhang; Liqun Huo; Zicheng Shao; Zefa Lu; Jiawei Zhang; Xiangcheng Li
Journal:  Oncotarget       Date:  2017-05-12

4.  Preoperative Serum Platelet-Lymphocyte Ratio as a Prognostic Factor in Cholangiocarcinoma Patients after Radical Resection: A Retrospective Analysis of 119 Patients.

Authors:  Ying Wu; Danyang Zhou; Guoping Zhang; Fengming Yi; Long Feng
Journal:  Gastroenterol Res Pract       Date:  2019-01-28       Impact factor: 2.260

5.  Surgical treatment of gallbladder cancer: An eight-year experience in a single center.

Authors:  Yasuyuki Kamada; Tomohide Hori; Hidekazu Yamamoto; Hideki Harada; Michihiro Yamamoto; Masahiro Yamada; Takefumi Yazawa; Masaki Tani; Asahi Sato; Ryotaro Tani; Ryuhei Aoyama; Yudai Sasaki; Masazumi Zaima
Journal:  World J Hepatol       Date:  2020-09-27

6.  Identification and Validation of Three Autophagy-Related Long Noncoding RNAs as Prognostic Signature in Cholangiocarcinoma.

Authors:  Ya Jun Liu; Alphonse Houssou Hounye; Zheng Wang; Xiaowei Liu; Jun Yi; Min Qi
Journal:  Front Oncol       Date:  2021-12-02       Impact factor: 6.244

7.  Expression levels of serum miRNA-195 in different types of patients with cholangiocarcinoma and its value to determine the prognosis thereof.

Authors:  Qingliang Chen; Congmei Wang; Hongkai Zhang; Yun Li; Yunhong Cao; Yongxiang Zhang; Shaokun Liu; Zhen Li; Xiaoguo Xin; Xinwei Han
Journal:  Oncol Lett       Date:  2018-02-09       Impact factor: 2.967

8.  Assessment of treatment outcomes in patients with advanced hilar cholangiocarcinoma (stages III-IV): Clinical significance of interventional therapy.

Authors:  Hai-Ping Zhao; Zheng-Hua Zhang; Ai-Hong Zheng
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.889

9.  Hepatectomy for gallbladder-cancer with unclassified anomaly of right-sided ligamentum teres: A case report and review of the literature.

Authors:  Toru Goto; Hiroaki Terajima; Takehito Yamamoto; Yoichiro Uchida
Journal:  World J Hepatol       Date:  2018-07-27

10.  miR-365 Suppresses Cholangiocarcinoma Cell Proliferation and Induces Apoptosis by Targeting E2F2.

Authors:  Lunjian Chen; Xiaorong Huang; Xinxin Chen
Journal:  Oncol Res       Date:  2018-02-22       Impact factor: 5.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.